TERADYNE, INC
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedule
15(a)(1) Financial Statements
The following consolidated financial statements are included in Item 8:
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP, PCAOB ID No 238) | 37 |
| Consolidated Balance Sheets as of December 31, 2025, and 2024 | 40 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | 41 |
| Consolidated Statements of Comprehensive Income for the years ended December 31, 2025, 2024 and 2023 | 42 |
| Consolidated Statements of Convertible Common Shares and Shareholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | 43 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | 44 |
15(a)(2) Financial Statement Schedule
The following consolidated financial statement schedule is included in Item 15(c):
Schedule II—Valuation and Qualifying Accounts
Schedules other than those listed above have been omitted since they are either not required or information is otherwise included.
15(a)(3) Listing of Exhibits
The Exhibits which are filed with this report or which are incorporated by reference herein are set forth in the Exhibit Index.
15(c) Financial Statement Schedules
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
| Column A | Column B | Column C | Column D | Column E | Column F |
|---|---|---|---|---|---|
| Description | Balance atBeginningof Period | AdditionsCharged toCost andExpenses | Other | Deductions | Balance atEnd of Period |
| (in thousands) | |||||
| Valuation reserve deducted in the balance sheet from the asset to which it applies: | |||||
| Accounts receivable: | |||||
| 2025 Allowance for credit losses | $2,111 | $442 | $68 | $211 | $2,410 |
| 2024 Allowance for credit losses | $1,988 | $149 | $(36) | $(10) | $2,111 |
| 2023 Allowance for credit losses | $1,955 | $301 | $23 | $291 | $1,988 |
| Column A | Column B | Column C | Column D | Column E | Column F |
|---|---|---|---|---|---|
| Description | Balance atBeginningof Period | AdditionsCharged toCost andExpenses | Other | Deductions | Balance atEnd of Period |
| (in thousands) | |||||
| Valuation reserve deducted in the balance sheet from the asset to which it applies: | |||||
| Deferred taxes: | |||||
| 2025 Valuation allowance | $117,254 | $7,709 | $96 | $997 | $124,062 |
| 2024 Valuation allowance | $109,251 | $8,809 | $(41) | $765 | $117,254 |
| 2023 Valuation allowance | $103,807 | $5,759 | $59 | $374 | $109,251 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.